Removal of gadolinium by peritoneal dialysis.
An association between gadolinium-containing contrast and the development of nephrogenic systemic fibrosis (NSF) has been increasingly recognized. For patients receiving hemodialysis (HD) who are exposed to gadolinium, the Federal Drug Administration (FDA) recommends HD to remove this contrast agent in order to minimize the risk of NSF. This study examines if gadolinium can be removed by frequent exchanges by peritoneal dialysis (PD). Following administration of 0.1 mmol/kg of gadodiamide to a patient with end-stage renal disease, the serum clearance of this contrast agent by automated PD was examined. 10 and 15 exchanges of PD using an automated cycler were respectively performed during the first and second 24-hour periods after gadolinium exposure. Serum gadolinium levels were measured 1 hour after the gadolinium administration, then at 24 and 48 hours after PD was initiated. 90% of the gadolinium was removed from the circulation in 2 days with a regimen of 10-15 exchanges per day of PD. For patients on chronic maintenance PD who receive gadolinium, our case suggests that a temporary intensive automated PD regimen, aimed at maximizing clearance of this contrast agent immediately after exposure, could be an effective alternative when institution of HD is problematic.
Murashima
M
M
Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Drott
H R
HR
Carlow
D
D
Shaw
L M
LM
Milone
M
M
Bachman
M
M
Tsai
D E
DE
Yang
S-L
SL
Bloom
R D
RD
D003287:Contrast Media / Q000009:adverse effects / Q000493:pharmacokinetics*; D005355:Fibrosis; D005682:Gadolinium / Q000009:adverse effects / Q000493:pharmacokinetics*; D019786:Gadolinium DTPA / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D012871:Skin Diseases / Q000139:chemically induced / Q000517:prevention & control
D003287:Contrast Media; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA